AVR
$9.40
+$0.47 (5.26%)+5.26%
ClosedLoading chart...
IndexN/A
Market Cap0.91B
Enterprise Value0.17B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-4.22
P/S96.28
P/B-1980.52
P/C-2.31
EV/EBITDA-1.88
EV/SalesN/A
EPS (ttm)-2.23
EarningsN/A
Gross Margin-16.57%
Oper. Margin-4908.21%
Profit Margin-4921.28%
Volume0.68M
Shs Outstand0.10B
Change5.26%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $2.70M | $2.73M | $3.20M | $5.83M | $5.46M |
| Cost of Revenue | $1.44M | $1.86M | $2.90M | $3.93M | $2.10M |
| Gross Profit | $1.27M | $876.80K | $298.38K | $1.91M | $3.36M |
| Gross Margin | 46.84% | 32.06% | 9.32% | 32.68% | 61.53% |
| Operating Expenses | $79.64M | $49.02M | $31.41M | $18.77M | $16.62M |
| Operating Income | $-78.37M | $-48.14M | $-31.11M | $-16.86M | $-13.26M |
| Operating Margin | -2899.45% | -1760.26% | -972.11% | -289.18% | -242.99% |
| Net Income | $-76.29M | $-46.02M | $-30.56M | $-17.17M | $-11.78M |
| Net Margin | -2822.46% | -1682.81% | -954.91% | -294.50% | -215.78% |
| EPS (Basic) | $-3.77 | $-1.28 | $-0.85 | $-0.48 | $-0.33 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $80.70M | $30.53M | $15.99M | $21.43M | $9.75M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $18.02M | $11.63M | $6.95M | $10.91M | $7.90M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $62.76M | $19.30M | $9.03M | $10.52M | $1.86M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $62.76M | $19.30M | $9.03M | $10.52M | $1.86M |
| Total Liabilities & Stockholders Equity | $80.70M | $30.53M | $15.99M | $21.43M | $9.75M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Income | $-76.29M | $-46.02M | $-30.56M | $-17.17M | $-11.78M |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-61.24M | $-34.63M | $-29.42M | $-14.44M | $-11.08M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Anteris Advances Global PARADIGM Expansion with French Regulatory ClearanceGlobeNewswire Inc. Anteris Announces Results for the First Quarter of 2026GlobeNewswire Inc. Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM TrialGlobeNewswire Inc. Anteris Reports 2025 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital RaisesGlobeNewswire Inc. Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common StockGlobeNewswire Inc. Anteris Technologies Global Corp. Announces Pricing of $200 Million Public OfferingGlobeNewswire Inc. Anteris Announces Results for the Third Quarter of 2025GlobeNewswire Inc.
Show 7 more stories
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)GlobeNewswire Inc. Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of StockholdersGlobeNewswire Inc. Anteris Technologies Global Corp. Announces Postponement of Special Meeting of StockholdersGlobeNewswire Inc. Anteris Announces Results for the Second Quarter of 2025GlobeNewswire Inc. Anteris Appoints David Roberts and Gregory Moss to its Board of DirectorsGlobeNewswire Inc. Anteris Announces Results for the First Quarter of 2025GlobeNewswire Inc. Anteris Reports 2024 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Discover more
You may be interested in